KSI-501
Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy
Phase 3Active; First-in-class bispecific ABC
Key Facts
Indication
Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy
Phase
Phase 3
Status
Active; First-in-class bispecific ABC
Company
About Kodiak Sciences
Kodiak Sciences is a clinical-stage biopharma company with a mission to prevent and treat the leading causes of blindness through its proprietary Antibody Biopolymer Conjugate (ABC) platform. The company has achieved significant milestones, including positive Phase 3 topline results for its lead asset, Zenkuda (tarcocimab tedromer), in diabetic retinopathy and a BLA-ready profile. Its strategy is built on a deep, focused commitment to ophthalmology, leveraging its platform to develop durable, multi-mechanistic therapies that address fundamental unmet needs in retinal disease management.
View full company profile